Results 111 to 120 of about 1,352 (137)

B-cell imaging with zirconium-89 labelled rituximab PET-CT at baseline is associated with therapeutic response 24 weeks after initiation of rituximab treatment in rheumatoid arthritis patients [PDF]

A Roivainen, Alexandre Voskuyl, B Moller, Conny van der Laken, D Porter, Daniëlle Vugts, EH Elzinga, G Gebhart, GA Dongen van, Guus van Dongen, Hennie Raterman, I Verel, J Higashida, JC Edwards, JD Isaacs, JJ Haringman, K Muylle, Marc Huisman, Michel Tsang-A-Sjoe, MJ Hair de, MJ Vosjan, NE Makris, Otto Hoekstra, P Emery, Paul-Peter Tak, PP Tak, RM Thurlings, Stefan Bruijnen, T Jones, Tamara Ramwadhdoebe, YY Gent, YYJ Gent   +31 more
core   +1 more source

Radiolabeling of CHX-A″-DTPA-Antibody Conjugates with [⁸⁹Zr]ZrCl₄. [PDF]

J Nucl Med
Lyashchenko SK, Esposito TV, Tran T, Bauer D, Jones K, Park H, Carter LM, Pillarsetty NVK, Lewis JS.   +8 more
europepmc   +1 more source

The tumor targeting performance of anti-CD166 Probody drug conjugate CX-2009 and its parental derivatives as monitored by ⁸⁹Zr-immuno-PET in xenograft bearing mice. [PDF]

Theranostics, 2020
Chomet M, Schreurs M, Nguyen M, Howng B, Villanueva R, Krimm M, Vasiljeva O, van Dongen GAMS, Vugts DJ.   +8 more
europepmc   +1 more source

CD8 PET imaging with [⁸⁹Zr]Zr-berdoxam-crefmirlimab in patients with solid tumors: the Phase II iCorrelate study. [PDF]

J Immunother Cancer
Postow MA, Zang PD, Pal SK, Mauguen A, Farwell M, Gordon M, Hays D, Wong JYC, Chen D, Ulaner GA, Esposito G, McConathy J, Graham MM, Shields AF, Van den Abbeele AD, Butler MO, Thomas JS, Twardowski P, Narang J, Singh AP, Dey A, Maresca KP, Keliher E, Liu F, Potdevin G, Schmidt G, Le W, Wilson I, Mascioni A, Jia F, Korn R, Ferris MR, Schmiedehausen K, Pandit-Taskar N, Margolin KA.   +34 more
europepmc   +1 more source

Evaluating Radiotheranostic Targets for Endometrial Cancer. [PDF]

J Nucl Med
Sebastiano J, McGlone SA, Samuels ZV, Grimaldi C, Stoddard A, Galka S, Colaco E, Zeglis BM.   +7 more
europepmc   +1 more source

⁸⁹Zr-Immuno-PET: Toward a Noninvasive Clinical Tool to Measure Target Engagement of Therapeutic Antibodies In Vivo. [PDF]

J Nucl Med, 2019
Jauw YWS, O'Donoghue JA, Zijlstra JM, Hoekstra OS, Menke-van der Houven van Oordt CW, Morschhauser F, Carrasquillo JA, Zweegman S, Pandit-Taskar N, Lammertsma AA, van Dongen GAMS, Boellaard R, Weber WA, Huisman MC.   +13 more
europepmc   +1 more source

Anti-cancer immune priming with β-radioligand therapy using a novel high affinity antibody selectively targeting the 4Ig-Isoform of B7-H3. [PDF]

Theranostics
Glazer SE, Sutton MN, Yang P, Pisaneschi F, Sebastian M, Gammon ST, Piwnica-Worms D.   +6 more
europepmc   +1 more source

Synthesis and Evaluation of D8W, an Octadentate Desferrioxamine Analogue with Enhanced Water Solubility Designed for ⁸⁹Zr-ImmunoPET Imaging. [PDF]

Mol Pharm
Wood JL, Ghosh S, Rosser CA, Feeney SV, Brown CJM, Fletcher NL, Wheatcroft MP, Thurecht KJ, Codd R.   +8 more
europepmc   +1 more source

Advancing In Vivo Detection of T-Cell Function: Development and Preclinical Evaluation of ⁸⁹Zr-Ivuxolimab, a Human OX40 PET Tracer. [PDF]

J Nucl Med
Kalita M, Kuo RC, Reyes ST, Colburg DRC, Falk IN, Anders D, Vermesh O, Hayee S, Azevedo EC, Nagy SC, Deal EM, Chen AAD, Kong CS, Simonetta F, Giddabasappa A, Keliher EJ, Bartlett DW, Maresca KP, James ML, Alam IS.   +19 more
europepmc   +1 more source

Immuno-positron emission tomography as a new frontier in imaging hematologic malignancies. [PDF]

World J Clin Oncol
Goto H, Takano M, Shiraishi Y, Luanpitpong S.   +3 more
europepmc   +1 more source